- Home
- IBRX vs NVAX Comparison
IBRX vs NVAX Comparison
Compare IBRX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- NVAX
- Stock Information
- Founded
- IBRX 2014
- NVAX 1987
- Country
- IBRX United States
- NVAX United States
- Employees
- IBRX N/A
- NVAX N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBRX Health Care
- NVAX Health Care
- Exchange
- IBRX Nasdaq
- NVAX Nasdaq
- Market Cap
- IBRX 1.9B
- NVAX 2.0B
- IPO Year
- IBRX N/A
- NVAX 1995
- Fundamental
- Price
- IBRX $2.94
- NVAX $8.40
- Analyst Decision
- IBRX Strong Buy
- NVAX Buy
- Analyst Count
- IBRX 3
- NVAX 6
- Target Price
- IBRX $13.58
- NVAX $17.83
- AVG Volume (30 Days)
- IBRX 6.3M
- NVAX 4.5M
- Earning Date
- IBRX 11-12-2024
- NVAX 02-26-2025
- Dividend Yield
- IBRX N/A
- NVAX N/A
- EPS Growth
- IBRX N/A
- NVAX N/A
- EPS
- IBRX N/A
- NVAX N/A
- Revenue
- IBRX $7,332,000.00
- NVAX $885,193,000.00
- Revenue This Year
- IBRX $2,515.60
- NVAX N/A
- Revenue Next Year
- IBRX $766.19
- NVAX N/A
- P/E Ratio
- IBRX N/A
- NVAX N/A
- Revenue Growth
- IBRX 1218.71
- NVAX N/A
- 52 Week Low
- IBRX $2.28
- NVAX $3.53
- 52 Week High
- IBRX $10.53
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- IBRX 48.30
- NVAX 44.80
- Support Level
- IBRX $2.28
- NVAX $8.35
- Resistance Level
- IBRX $2.54
- NVAX $9.14
- Average True Range (ATR)
- IBRX 0.25
- NVAX 0.64
- MACD
- IBRX 0.10
- NVAX -0.06
- Stochastic Oscillator
- IBRX 64.71
- NVAX 19.85
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.